Cardiac Resynchronization Therapy in Patients with Ebstein's Anomaly
Genri Numata1, Eisuke Amiya1, Toshiya Kojima1
1Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
International Heart Journal
|October 3, 2017
Summary
Ebstein's anomaly patients with right ventricular pacing may develop pacemaker-induced cardiomyopathy. Cardiac resynchronization therapy (CRT) shows promise in treating this condition in these complex cases.
Area of Science:
- Cardiology
- Congenital Heart Disease
- Electrophysiology
Background:
- Ebstein's anomaly is a rare congenital heart defect affecting the tricuspid valve.
- Left ventricular (LV) dysfunction can coexist with Ebstein's anomaly.
- Right ventricular (RV) pacing can worsen LV function, leading to pacemaker-induced cardiomyopathy.
Observation:
- Patients with Ebstein's anomaly and LV dysfunction are at risk of accelerated pacemaker-induced cardiomyopathy from RV pacing.
- Even with preserved ejection fraction, RV pacing may exacerbate cardiac dysfunction in these patients.
Findings:
- This case report details the first instance of cardiac resynchronization therapy (CRT) effectively managing pacemaker-induced cardiomyopathy in a patient with Ebstein's anomaly.
- CRT demonstrated a positive effect on cardiac function in this specific clinical scenario.
Implications:
- Cardiac resynchronization therapy (CRT) may be a viable treatment option for pacemaker-induced cardiomyopathy in patients with Ebstein's anomaly.
- Further research is warranted to explore the role of CRT in managing complex cardiac conditions associated with congenital heart defects.
Keywords:
Pacemaker-induced cardiomyopathy
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
550
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
550
01:29Cardiomyopathy V: Interprofessional Care
506
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
506
01:30Cardiomyopathy II: Dilated Cardiomyopathy
634
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
01:23Cardiopulmonary Resuscitation III: AED Use
828
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
828
01:25Dysrhythmias VI: Management of Dysrhythmias
516
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
516
01:22Heart Failure VI: Adjunct Therapies
430
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
430